Trial Profile
Infusion Proof-of-concept Trial Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of FE 202158 in Patients With Vasodilatory Hypotension in Early Septic Shock
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Selepressin (Primary)
- Indications Hypotension; Septic shock
- Focus Proof of concept; Therapeutic Use
- Sponsors Ferring Pharmaceuticals
- 16 Aug 2014 New source identified and integrated (European Clinical Trials Database record: EudraCT2009-010798-19)
- 09 Apr 2014 New trial record